A new formulation is described based on biopolymeric microspheres containing alginate lyase (AL) and ciprofloxacin (Cip) for sustainable oral delivery in CF patients. Alginate (ALG) and high-methoxyl pectin (HMP) are selected as the biopolymers to develop a composite matrix. ALG microspheres coated with HMP and ALG-HMP blend are gelled in water/organic solvents mixtures, obtaining Cip encapsulations from 46.0 to 100.0%. ALG-HMP shows a Cip sustainable release profile and is able to encapsulate 90.0% of AL, showing 76.0% enzyme activity after release under simulated intestinal conditions. The developed system is a promising delivery carrier to treat chronic infection of Pseudomonas aeruginosa and to reduce the viscoelasticity of the mucus accumulated into intestine of CF patients.
No takes yet. Share an insight, caveat, or question.
Islan et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: